Bryant Lim
Vermogen: 153 440 $ op 31-08-2026
Vermogen: 153 440 $ op 31-08-2026
Bryant D.
Lim is currently Director at Life Sciences Pennsylvania since 2019.
Mr. Lim is also CFO, Secretary, and Chief Legal Officer at Prelude Therapeutics, Inc. starting in 2024.
Formerly, Mr. Lim was Chief Business Officer, SVP, and General Counsel at Aceragen, Inc. from 2022 to 2023.
Mr. Lim was Secretary, Senior VP, and General Counsel at Idera Pharmaceuticals, Inc. from 2018 to 2022.
Mr. Lim was Chief Compliance Officer and Vice President at Incyte Corp.
from 2014 to 2018.
Mr. Lim worked as Assistant Counsel at Merck & Co., Inc. and as Associate General Counsel at Viropharma, Inc. Education includes undergraduate studies at Rochester Christian University and graduate studies at Villanova University School of Law.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 27-04-2026 | 27.400 ( 0,04% ) | 153 440 $ | 31-08-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Financieel Directeur/CFO | 08-04-2024 |
Life Sciences Pennsylvania
Life Sciences Pennsylvania Miscellaneous Commercial ServicesCommercial Services Provides consulting services to biosciences industry | Directeur/Bestuurslid | 01-05-2019 |
| Bedrijven | Functie | Einde |
|---|---|---|
| ACERAGEN, INC. | Algemeen Adviseur | 17-02-2023 |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Algemeen Adviseur | 01-10-2022 |
| INCYTE CORPORATION | Compliance Officer | 01-09-2018 |
Viropharma, Inc. | Corporate Officer/Principal | - |
| MERCK & CO., INC. | Algemeen Adviseur | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 9 |
|---|---|
Incyte Corp.
Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Rochester Christian University
Rochester Christian University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Life Sciences Pennsylvania
Life Sciences Pennsylvania Miscellaneous Commercial ServicesCommercial Services Provides consulting services to biosciences industry | Commercial Services |
Villanova University School of Law
Villanova University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prelude Therapeutics, Inc.
Prelude Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines targeting chromatin function to treat cancer and rare diseases | Health Technology |
Viropharma, Inc. | |
Aceragen, Inc.
Aceragen, Inc. BiotechnologyHealth Technology Discovers, develops, and commercializes therapeutics for oncology and rare diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau